IMR Press / FBL / Volume 12 / Issue 7 / DOI: 10.2741/2396

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Transforming growth factor-beta signaling in breast cancer
Show Less
1 Department of Medical Microbiology, Immunology, and Cell Biology, SimmonsCooper Cancer Institute, Southern Illinois University School of Medicine. 913 N. Rutledge Street, Springfield, IL 62702, USA
2 Department of Medicine, Geriatric Research, Southern Illinois University School of Medicine. 801 N. Rutledge Street, Springfield, IL 62794, USA
Academic Editor:Kounosuke Watabe
Front. Biosci. (Landmark Ed) 2007, 12(7), 4393–4401; https://doi.org/10.2741/2396
Published: 1 May 2007
(This article belongs to the Special Issue Pathogenesis of tumor progression in breast and prostate cancer)
Abstract

Transforming growth factor-β (TGF-β) is a multifunctional polypeptide that regulates cell growth, differentiation, and extracellular matrix formation. Studies on genetically engineered animal models have demonstrated that TGF-β-mediated signaling pathway plays a critical role in both normal development and tumorigenesis of the breast. In pathogenesis of breast cancer, the role of TGF-β appears featured with growth-inhibitory effects at early stages of carcinogenesis, but aggressive oncogenesis with transition to more advanced malignant states. The TGF-β signaling pathway is also tissue-context and ligand content-dependent. Therein, therapeutic modulation of TGF-β signaling may be a multifactorial event.

Share
Back to top